≪英文≫

Detection of semenogelin 1 amyloidosis through immunohistochemical staining with novel antiserum developed based on mass spectrometric peptide mapping analysis.

Tasaki M, Misumi Y, Nomura T, Kamba T, Ueda M.

Amyloid. 2022;29(4):278-280.

 

Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.

Koshiro N, Nakajima K, Oyama M, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators.

Int J Urol. 2022;29(12):1477-1487.

 

Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias.

Otsuka H, Kita Y, Ito K, Sano T, Inokuchi J, Tomida R, Takahashi A, Matsumoto K, Kurahashi R, Ozaki Y, Uegaki M, Maruyama S, Mukai S, Tsutsumi M, Kawahara T, Segawa T, Kitamura H, Morita S, Kobayashi T.

Cancer Sci. 2022;113(11):3912-3921.

 

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Powles T , Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators.

(Murakami Yoji is indicated in List of Investigators, Supplementary Appendix.)

Lancet Oncol. 2022;23(9):1133-1144.

 

Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report.

Uekawa A, Kurahashi R, Motoshima T, Murakami Y, Yatsuda J, Kamba T.

Urol Case Rep. 2022;45:102198. doi: 10.1016/j.eucr.2022.102198.

 

Clear cell carcinoma of the seminal vesicle in a young adult.

Murakami H, Motoshima T, Kurahashi R, Murakami Y, Sugiyama Y, Yamaguchi T, Yatsuda J, Asato T, Mikami Y, Kamba T.

IJU Case Rep. 2022;5(5):406-409.

 

Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.

Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group.

(Kurahashi R is indicated in Acknowledgement.)

BJU Int. 2022;130(2):226-234.

 

Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association.

Yamaguchi T, Sugiyama Y, Tanaka T, Kimura T, Yumura Y, Nakano M, Sugiyama T, Miura N, Goya M, Yamamoto A, Takahashi S, Miura Y, Tsuzuki T, Masumori N, Nishiyama H, Yao M, Koie T, Miyake H, Saika T, Saito S, Akimoto T, Tamada T, Ando Y, Takahashi S, Suzuki T, Hinotsu S, Kamba T.

Int J Urol. 2022;29(8):780-792.

 

Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate.

Funasaki S, Mehanna S, Ma W, Nishizawa H, Kamikubo Y, Sugiyama H, Ikeda S, Motoshima T, Hasumi H, Linehan WM, Schmidt LS, Rickett C, Suda T, Oike Y, Kamba T, Baba M.

Cancer Sci. 2022;113(7):2352-2367.

 

Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events.

Tsukamoto H, Komohara Y, Tomita Y, Miura Y, Motoshima T, Imamura K, Kimura T, Ikeda T, Fujiwara Y, Yano H, Kamba T, Sakagami T, Oshiumi H.

Proc Natl Acad Sci USA. 2022;119(29):e2205378119.

 

Subcapsular renal hematoma after ureterorenoscopy.

Harada N, Yatsuda J, Kurahashi R, Fukushima Y, Segawa T, Motoshima T, Murakami Y, Yamaguchi T,Sugiyama Y, Kamba T.

IJU Case Rep. 2022;5(4):281-285.

 

Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.

Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Hirokoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H.

Anticancer Res. 2022;42(6):3099-3108.

 

Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis.

Mukai S, Sakamoto N, Kakinoki H, Shibuya T, Morita R, Nishihara K, Noguchi M, Shin T, Fujimoto N, Igawa T, Ishii T, Haga N, Enokida H, Eto M, Kamba T, Sakai H, Saito S, Terada N, Kamoto T.

J Clin Med. 2022;11(12):3538.

 

STAT3 polymorphism associates with mTOR inhibitor-induced interstitial lung disease in patients with renal cell carcinoma.

Yamamoto K, Ioroi T, Shinomiya K, Yoshida A, Harada K, Fujisawa M, Omura T, Ikemi Y, Nakagawa S, Yonezawa A, Ogawa O, Matsubara K, Iwamoto T, Nishikawa K, Hayashi S, Tohara D, Murakami Y, Motoshima T, Joho H, Yano I.

Oncol Res. 2022;29(1):11-23.

 

Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.

Mizokami A, Nishimoto K, Matsuyama H, Ichikawa T, Takahashi S, Shiina H, Hashine K, Sugiyama Y, Kamiyama M, Enokida H, Nakajima K.

Anticancer Res. 2022;42(3):1465-1475.

 

Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.

Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, Morita S, Ogawa O, Nishiyama H, Kitamura H, Sugimoto M; Japan Urological Oncology Group.

(Kurahashi R is indicated in Acknowledgement.)

Urol Oncol. 2022;40(3):107.e1-107.e9.

 

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.

Kobayashi T, Ito K, Kojima T, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group.

(Kumamoto University Department of Urology participates in JUOG and provided the data to this study.)

Cancer Immunol Immunother. 2022;71(2):461-471.

 

Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.

Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Abe H, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group.

(Kurahashi R is indicated in Acknowledgement.)

J Geriatr Oncol. 2022;13(1):88-93.

 

≪和文≫

術前診断に難渋した肝副腎癒合に合併した右副腎腺腫の1例

今藤淳之助, 倉橋竜磨, 福島結美, 元島崇信, 村上洋嗣, 矢津田旬二, 山口隆大, 杉山豊, 神波大己

西日泌尿. 2022;85(2):52-56.

 

自然退縮した特発性陰茎海綿体膿瘍の1例

石﨑宏志, 元島崇信, 倉橋竜磨, 福島結美, 脊川卓也, 村上洋嗣, 矢津田旬二, 山口隆大, 杉山豊, 神波大己

西日泌尿. 2022;84(6):656-659.

 

腎細胞癌に対するリンパ節郭清の後ろ向き検討

鈴木良輔，後藤崇之，吉野喬之，澤田篤郎，赤松秀輔，齊藤亮一，小林恭，山﨑俊成，井上貴博，神波大己，小川修

泌尿紀要. 2022;68(6):165-170.

 

自己免疫性溶血性貧血に併発しステロイドが有効であった増殖性膀胱炎の1例

笹岡祐次, 脊川卓也, 倉橋竜磨, 福島結美, 元島崇信, 村上洋嗣, 矢津田旬二, 山口隆大, 杉山豊, 神波大己

西日泌尿. 2022;84(5):583-587.

 

九州沖縄地区における尿膜管癌診療の診療実態調査報告

東武昇平, 有働和馬, 西原聖顕, 宮島茂郎, 安藤忠助, 鬼塚千衣, 井手迫俊彦, 芦刈明日香, 計屋知彰, 井川掌, 田中正利, 秦聡孝, 賀本敏行, 中川昌之, 斎藤誠一, 酒井英樹, 江藤正俊, 神波大己, 藤本直浩, 野口満

西日泌尿. 2022;84(5):514-519.